Ichthyosis, a rare genetic skin disorder, presents significant daily challenges for those affected, compelling them to adhere to labor-intensive skincare routines. Unfortunately, this debilitating condition has not captured major pharmaceutical interest, leaving dedicated dermatologists to
The COVID-19 pandemic presented a global challenge, with governments and health institutions striving to contain the virus amid misinformation and rapid transmission. One pivotal approach was the development of various COVID-19 vaccine trials, employing adaptive methods to expedite recruitment
The recent announcement by Russia regarding the development of a groundbreaking mRNA cancer vaccine represents a significant milestone in the global fight against cancer. Scheduled for free distribution in early 2025, this innovative vaccine has captured worldwide attention due to its potential to
5-Fluorouracil (5-FU) has been a cornerstone in cancer treatment for decades, primarily believed to work by damaging DNA and preventing cancer cells from replicating. However, recent research suggests that 5-FU's primary mechanism of action may be through targeting RNA, particularly ribosomal
MilliporeSigma, the Life Science business of Merck KGaA in the U.S. and Canada, has announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). This acquisition marks a significant step forward in enhancing their 2D and 3D cell culture portfolio with the innovative technology of
A groundbreaking study led by Natasha Chang at McGill University has shown that a novel drug, K884, holds promise for treating Duchenne muscular dystrophy (DMD), a devastating genetic disorder characterized by severe muscle degeneration. Unlike conventional treatments, which primarily focus on
